+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
LAMEA Biosimulation Market Size, Share & Trends Analysis Report By Product, By Pricing Model, By End Use, By Application, By Deployment Model, By Therapeutic Area, By Country and Growth Forecast, 2024 - 2031- Product Image
LAMEA Biosimulation Market Size, Share & Trends Analysis Report By Product, By Pricing Model, By End Use, By Application, By Deployment Model, By Therapeutic Area, By Country and Growth Forecast, 2024 - 2031- Product Image
New

LAMEA Biosimulation Market Size, Share & Trends Analysis Report By Product, By Pricing Model, By End Use, By Application, By Deployment Model, By Therapeutic Area, By Country and Growth Forecast, 2024 - 2031

  • PDF Icon

    Report

  • 184 Pages
  • December 2024
  • Region: Africa, Middle East
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 6036033
Description Jump to:
The Latin America, Middle East and Africa Biosimulation Market is expected to witness market growth of 19.4% CAGR during the forecast period (2024-2031).

The Brazil market dominated the LAMEA Biosimulation Market by country in 2023, and is expected to continue to be a dominant market till 2031; thereby, achieving a market value of $215.1 million by 2031. The Argentina market is showcasing a CAGR of 20.1% during 2024-2031. Additionally, the UAE market would register a CAGR of 19.1% during 2024-2031.



For biosimilars, they ensures their equivalence to original biologics by simulating pharmacokinetic and pharmacodynamic (PK/PD) profiles. This reduces the need for extensive comparative trials, saving time and resources. For instance, this has been used to demonstrate the bioequivalence of insulin biosimilars, ensuring they perform identically to the original products.

While traditionally focused on pharmaceuticals, this is increasingly applied across diverse fields, significantly expanding its market scope. In the field of toxicology, this is transforming chemical safety evaluations by modeling the impacts of hazardous agents on biological systems, thereby diminishing the reliance on animal testing.

The UAE’s strategic focus on becoming a global healthcare and biotechnology hub has driven this adoption. Programs like the National Strategy for Advanced Innovation aim to integrate cutting-edge technologies into various sectors, including healthcare. Dubai Healthcare City and Abu Dhabi’s Mubadala Healthcare have partnered with global pharmaceutical companies to explore this for personalized medicine and clinical trial optimization. Additionally, the UAE’s focus on medical tourism and incorporating smart technologies into its healthcare infrastructure are key drivers of market growth. These advancements highlight the UAE’s commitment to becoming a regional leader in healthcare innovation, making it a lucrative market for biosimulation technologies. Hence, the regional market will grow rapidly in the coming years.

List of Key Companies Profiled

  • Certara, Inc.
  • Dassault Systemes SE
  • Advanced Chemistry Development, Inc.
  • Genedata AG (Danaher Corporation)
  • Instem Group of Companies
  • Chemical Computing Group ULC
  • Simulations Plus, Inc.
  • Schrodinger, Inc.
  • PPD, Inc. (Thermo Fisher Scientific, Inc.)
  • Physiomics Plc

Market Report Segmentation

By Product
  • Software
  • Molecular Modeling & Simulation Software
  • Clinical Trial Design Software
  • PK/PD Modeling and Simulation Software
  • Pbpk Modeling and Simulation Software
  • Toxicity Prediction Software
  • Other Software Type
  • Services
  • Contract Services
  • Consulting
  • Other Services Type
By Pricing Model
  • License-based Model
  • Subscription-based Model
  • Service-based Model
  • Pay Per Use Model
By End Use
  • Life Sciences Companies
  • Academic Research Institutions
  • Other End Use
By Application
  • Drug Discovery & Development
  • Disease Modeling
  • Other Application
By Deployment Model
  • Cloud-based
  • On-premises
  • Hybrid Model
By Therapeutic Area
  • Oncology
  • Cardiovascular Disease
  • Infectious Disease
  • Neurological Disorders
  • Other Therapeutic Area
By Country
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Biosimulation Market, by Product
1.4.2 LAMEA Biosimulation Market, by Pricing Model
1.4.3 LAMEA Biosimulation Market, by End Use
1.4.4 LAMEA Biosimulation Market, by Application
1.4.5 LAMEA Biosimulation Market, by Deployment Model
1.4.6 LAMEA Biosimulation Market, by Therapeutic Area
1.4.7 LAMEA Biosimulation Market, by Country
1.5 Methodology for the Research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
Chapter 4. Competition Analysis - Global
4.1 Market Share Analysis, 2023
4.2 Strategies Deployed in Biosimulation Market
4.3 Porter Five Forces Analysis
Chapter 5. LAMEA Biosimulation Market by Product
5.1 LAMEA Software Market by Country
5.2 LAMEA Biosimulation Market by Software Type
5.2.1 LAMEA Molecular Modeling & Simulation Software Market by Country
5.2.2 LAMEA Clinical Trial Design Software Market by Country
5.2.3 LAMEA PK/PD Modeling and Simulation Software Market by Country
5.2.4 LAMEA Pbpk Modeling and Simulation Software Market by Country
5.2.5 LAMEA Toxicity Prediction Software Market by Country
5.2.6 LAMEA Other Software Type Market by Country
5.3 LAMEA Services Market by Country
5.4 LAMEA Biosimulation Market by Services Type
5.4.1 LAMEA Contract Services Market by Country
5.4.2 LAMEA Consulting Market by Country
5.4.3 LAMEA Other Services Type Market by Country
Chapter 6. LAMEA Biosimulation Market by Pricing Model
6.1 LAMEA License-based Model Market by Country
6.2 LAMEA Subscription-based Model Market by Country
6.3 LAMEA Service-based Model Market by Country
6.4 LAMEA Pay Per Use Model Market by Country
Chapter 7. LAMEA Biosimulation Market by End Use
7.1 LAMEA Life Sciences Companies Market by Country
7.2 LAMEA Academic Research Institutions Market by Country
7.3 LAMEA Other End Use Market by Country
Chapter 8. LAMEA Biosimulation Market by Application
8.1 LAMEA Drug Discovery & Development Market by Country
8.2 LAMEA Disease Modeling Market by Country
8.3 LAMEA Other Application Market by Country
Chapter 9. LAMEA Biosimulation Market by Deployment Model
9.1 LAMEA Cloud-based Market by Country
9.2 LAMEA On-premises Market by Country
9.3 LAMEA Hybrid Model Market by Country
Chapter 10. LAMEA Biosimulation Market by Therapeutic Area
10.1 LAMEA Oncology Market by Country
10.2 LAMEA Cardiovascular Disease Market by Country
10.3 LAMEA Infectious Disease Market by Country
10.4 LAMEA Neurological Disorders Market by Country
10.5 LAMEA Other Therapeutic Area Market by Country
Chapter 11. LAMEA Biosimulation Market by Country
11.1 Brazil Biosimulation Market
11.1.1 Brazil iosimulation Market by Product
11.1.1.1 Brazil Biosimulation Market by Software Type
11.1.1.2 Brazil Biosimulation Market by Services Type
11.1.2 Brazil Biosimulation Market by Pricing Model
11.1.3 Brazil Biosimulation Market by End Use
11.1.4 Brazil Biosimulation Market by Application
11.1.5 Brazil Biosimulation Market by Deployment Model
11.1.6 Brazil Biosimulation Market by Therapeutic Area
11.2 Argentina Biosimulation Market
11.2.1 Argentina Biosimulation Market by Product
11.2.1.1 Argentina Biosimulation Market by Software Type
11.2.1.2 Argentina Biosimulation Market by Services Type
11.2.2 Argentina Biosimulation Market by Pricing Model
11.2.3 Argentina Biosimulation Market by End Use
11.2.4 Argentina Biosimulation Market by Application
11.2.5 Argentina Biosimulation Market by Deployment Model
11.2.6 Argentina Biosimulation Market by Therapeutic Area
11.3 UAE Biosimulation Market
11.3.1 UAE Biosimulation Market by Product
11.3.1.1 UAE Biosimulation Market by Software Type
11.3.1.2 UAE Biosimulation Market by Services Type
11.3.2 UAE Biosimulation Market by Pricing Model
11.3.3 UAE Biosimulation Market by End Use
11.3.4 UAE Biosimulation Market by Application
11.3.5 UAE Biosimulation Market by Deployment Model
11.3.6 UAE Biosimulation Market by Therapeutic Area
11.4 Saudi Arabia Biosimulation Market
11.4.1 Saudi Arabia Biosimulation Market by Product
11.4.1.1 Saudi Arabia Biosimulation Market by Software Type
11.4.1.2 Saudi Arabia Biosimulation Market by Services Type
11.4.2 Saudi Arabia Biosimulation Market by Pricing Model
11.4.3 Saudi Arabia Biosimulation Market by End Use
11.4.4 Saudi Arabia Biosimulation Market by Application
11.4.5 Saudi Arabia Biosimulation Market by Deployment Model
11.4.6 Saudi Arabia Biosimulation Market by Therapeutic Area
11.5 South Africa Biosimulation Market
11.5.1 South Africa Biosimulation Market by Product
11.5.1.1 South Africa Biosimulation Market by Software Type
11.5.1.2 South Africa Biosimulation Market by Services Type
11.5.2 South Africa Biosimulation Market by Pricing Model
11.5.3 South Africa Biosimulation Market by End Use
11.5.4 South Africa Biosimulation Market by Application
11.5.5 South Africa Biosimulation Market by Deployment Model
11.5.6 South Africa Biosimulation Market by Therapeutic Area
11.6 Nigeria Biosimulation Market
11.6.1 Nigeria Biosimulation Market by Product
11.6.1.1 Nigeria Biosimulation Market by Software Type
11.6.1.2 Nigeria Biosimulation Market by Services Type
11.6.2 Nigeria Biosimulation Market by Pricing Model
11.6.3 Nigeria Biosimulation Market by End Use
11.6.4 Nigeria Biosimulation Market by Application
11.6.5 Nigeria Biosimulation Market by Deployment Model
11.6.6 Nigeria Biosimulation Market by Therapeutic Area
11.7 Rest of LAMEA Biosimulation Market
11.7.1 Rest of LAMEA Biosimulation Market by Product
11.7.1.1 Rest of LAMEA Biosimulation Market by Software Type
11.7.1.2 Rest of LAMEA Biosimulation Market by Services Type
11.7.2 Rest of LAMEA Biosimulation Market by Pricing Model
11.7.3 Rest of LAMEA Biosimulation Market by End Use
11.7.4 Rest of LAMEA Biosimulation Market by Application
11.7.5 Rest of LAMEA Biosimulation Market by Deployment Model
11.7.6 Rest of LAMEA Biosimulation Market by Therapeutic Area
Chapter 12. Company Profiles
12.1 Certara, Inc.
12.1.1 Company Overview
12.1.2 Financial Analysis
12.1.3 Regional Analysis
12.1.4 Research & Development Expenses
12.1.5 Recent Strategies and Developments
12.1.5.1 Product Launches and Product Expansions
12.1.5.2 Acquisition and Mergers
12.1.6 SWOT Analysis
12.2 Dassault Systemes SE
12.2.1 Company Overview
12.2.2 Financial Analysis
12.2.3 Regional Analysis
12.2.4 Research & Development Expense
12.2.5 SWOT Analysis
12.3 Advanced Chemistry Development, Inc.
12.3.1 Company Overview
12.4 Genedata AG (Danaher Corporation)
12.4.1 Company Overview
12.4.2 Financial Analysis
12.4.3 Segmental and Regional Analysis
12.4.4 Research & Development Expense
12.4.5 Recent Strategies and Developments
12.4.5.1 Partnerships, Collaborations, and Agreements
12.5 Instem Group of Companies
12.5.1 Company Overview
12.6 Chemical Computing Group ULC
12.6.1 Company Overview
12.7 Simulations Plus, Inc.
12.7.1 Company Overview
12.7.2 Financial Analysis
12.7.3 Segmental and Regional Analysis
12.7.4 Research & Development Expenses
12.7.5 Recent Strategies and Developments
12.7.5.1 Partnerships, Collaborations, and Agreements
12.7.5.2 Product Launches and Product Expansions
12.7.5.3 Acquisition and Mergers
12.7.6 SWOT Analysis
12.8 Schrodinger, Inc.
12.8.1 Company Overview
12.8.2 Financial Analysis
12.8.3 Segmental and Regional Analysis
12.8.4 Research & Development Expenses
12.9 PPD, Inc. (Thermo Fisher Scientific, Inc.)
12.9.1 Company Overview
12.9.2 Financial Analysis
12.9.3 Segmental and Regional Analysis
12.9.4 Research & Development Expenses
12.10. Physiomics Plc
12.10.1 Company Overview
12.10.2 Financial Analysis

Companies Mentioned

  • Certara, Inc.
  • Dassault Systemes SE
  • Advanced Chemistry Development, Inc.
  • Genedata AG (Danaher Corporation)
  • Instem Group of Companies
  • Chemical Computing Group ULC
  • Simulations Plus, Inc.
  • Schrodinger, Inc.
  • PPD, Inc. (Thermo Fisher Scientific, Inc.)
  • Physiomics Plc

Methodology

Loading
LOADING...

Related Topics

Related Reports

Biosimulation Market Size, Share & Trends Analysis Report By Product, By Pricing Model, By End Use, By Application, By Deployment Model, By Therapeutic Area, By Regional Outlook and Forecast, 2024 - 2031 - Product Image

Biosimulation Market Size, Share & Trends Analysis Report By Product, By Pricing Model, By End Use, By Application, By Deployment Model, By Therapeutic Area, By Regional Outlook and Forecast, 2024 - 2031

  • Report
  • 477 Pages
  • Global
From
Biosimulation Market By Product, By Application, By Delivery model, By End User: Global Opportunity Analysis and Industry Forecast, 2023-2032 - Product Image

Biosimulation Market By Product, By Application, By Delivery model, By End User: Global Opportunity Analysis and Industry Forecast, 2023-2032

  • Report
  • 435 Pages
  • Global
From
Biosimulation Market Size, Share & Trends Analysis Report By Product (Software, Services), By Application, Therapeutic Area, By Deployment Model, By Pricing Model, By End Use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Biosimulation Market Size, Share & Trends Analysis Report By Product (Software, Services), By Application, Therapeutic Area, By Deployment Model, By Pricing Model, By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Europe Biosimulation Market Size, Share & Trends Analysis Report By Product, By Pricing Model, By End Use, By Application, By Deployment Model, By Therapeutic Area, By Country and Growth Forecast, 2024 - 2031 - Product Image

Europe Biosimulation Market Size, Share & Trends Analysis Report By Product, By Pricing Model, By End Use, By Application, By Deployment Model, By Therapeutic Area, By Country and Growth Forecast, 2024 - 2031

  • Report
  • 185 Pages
  • Europe
From
Asia-Pacific Biosimulation Market Size, Share & Trends Analysis Report By Product, By Pricing Model, By End Use, By Application, By Deployment Model, By Therapeutic Area, By Country and Growth Forecast, 2024 - 2031 - Product Image

Asia-Pacific Biosimulation Market Size, Share & Trends Analysis Report By Product, By Pricing Model, By End Use, By Application, By Deployment Model, By Therapeutic Area, By Country and Growth Forecast, 2024 - 2031

  • Report
  • 186 Pages
  • Asia Pacific
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.